Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia
Observational Study on the Use of Canakinumab Administered Subcutaneously in the Treatment of Patients With COVID-19 Pneumonia
Sponsor: AUSL Romagna Rimini
Terminated
due to covid
Listed as NCT04348448, this observational or N/A phase trial focuses on COVID-19 and remains terminated or withdrawn. Sponsored by AUSL Romagna Rimini, it has been updated 6 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Aug 2023 — Jul 2024 [monthly]
Terminated
Status: Unknown Status → Terminated
-
May 2022 — Aug 2023 [monthly]
Unknown Status
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — May 2022 [monthly]
Not Yet Recruiting
▶ Show 1 earlier version
-
May 2020 — Jan 2021 [monthly]
Not Yet Recruiting
First recorded
Feb 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AUSL Romagna Rimini
For direct contact, visit the study record on ClinicalTrials.gov .